GLIPR2

Across TCGA pan-cancer cohorts, GLIPR2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of GLIPR2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GLIPR2 RNA is repressed in tumor relative to normal tissue. In most cancer types GLIPR2 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

LUAD, COAD, and KIRC are the cancer types where GLIPR2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLIPR2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	−2.283	<.001	11	view →
COAD	All	IV	−1.787	<.001	11	view →
KIRC	Male	IV	+1.322	<.001	11	view →
LUSC	Female	II,III,IV	−2.555	<.001	8	view →
BLCA	All	All	−1.317	<.001	8	view →
KIRP	All	All	+0.915	<.001	7	view →
UCEC	All	All	−1.779	<.001	6	view →
HNSC	Female	All	+0.968	.012	6	view →
BRCA	All	III,IV	−0.846	<.001	6	view →
THCA	All	All	−0.543	<.001	6	view →
KICH	Female	All	−1.731	<.001	5	view →
LIHC	All	II,III,IV	+0.863	.002	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

GLIPR2–LUAD

Open the LUAD breakdown →